scholarly journals Cardiomyopathy in Pregnancy: A Review Literature

2021 ◽  
Vol 2 (1) ◽  
pp. 16-24
Author(s):  
Ayu Asri Devi Adityawati ◽  
Anna Fuji Rahimah ◽  
Heny Martini ◽  
Cholid Tri Tjahjono

BACKGROUND: Pregnancy is an experience that many women can achieve. Pregnancy is generally well tolerated in asymptomatic patients with cardiomyopathies but in restrictive form cardiomyopathy, pregnancy cannot be tolerated because of poor prognosis. Prior cardiac events, poor functional class (New York Heart Association class III or IV), or advanced left ventricular systolic dysfunction are present, the risk of maternal cardiac complications during pregnancy are markedly increased. Worsening of the clinical condition can occur during pregnancy, despite intensive medical treatment. Although the incident of cardiovascular disease is present 0.5-4% in developed countries, our knowledge about various of cardiomyopathy and pregnancy should be updateable. CONCLUSION: Our literature provide three types of cardiomyopathy in pregnancy with an example condition for each type that relevant during pregnancy. Peripartum cardiomyopathy is the most common form of cardiomyopathy occured in pregnancy therefore a thorough review is needed to give best outcome for pregnancy. Arryhtmia is the commonnest form in hypertrophic cardiomyopathy which need to be regularly monitored and measure should be taken if the arryhtmia is life threatening for mother and the child. Cardiac amyloidosis is the common form of restrictive cardiomyopathy in pregnancy.

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 1028-1028
Author(s):  
C. C. Portera ◽  
J. M. Walshe ◽  
N. Denduluri ◽  
A. W. Berman ◽  
U. Vatas ◽  
...  

1028 Background: T and P are humanized recombinant monoclonal antibodies (MoAB) that target different epitopes of HER2 extracellular domain. P blocks HER2’s ability to heterodimerize with other HER/ErbB receptors. Methods: This Ph II trial evaluates the efficacy and safety of T with P in patients (pts) with HER2+ (FISH +) MBC who had progressive disease (PD) on T-based therapy. Eligible pts must have had = 3 T-based regimens, normal (nl) left ventricular ejection fraction (EF=55%) and without significant cardiac history. Pts received IV T (6mg/kg) and P (420 mg) every 3 weeks (wks). EKG plus echocardiogram (ECHO) or cardiac MRI and tumor response were assessed every 3 and 6 wks, respectively. Results: Eleven pts received 39 (1 to 13) cycles, 1 pt achieved a partial response (PR) and 3 pts had stable disease. A total of 68 ECHOs and 8 cardiac MRIs were performed. Left ventricular systolic dysfunction (LVSD) with nl EKG was seen in 5 pts; Grade (Gr) 1 (n = 2) (EF 50–55%), Gr 2 (n = 2) (EF 40–50%) and Gr 3 (n = 1) (EF20–40%). Gr 2–3 events were associated with global hypokinesis. Gr 3 event was associated with symptomatic CHF. All 5 pts had received 240mg/m2 cumulative dose of doxorubicin, 2 pts (Gr 2–3) received chest wall radiation, and 1 pt (Gr 1) had HTN. Two pts with Gr 1–2 LVSD had a history of reduced EF during prior T-based treatment, which reversed to nl upon stopping T. Reduced EF appeared within 1–2 cycles, which returned to nl in 3 pts within 1wk to 3 months (mo) post discontinuing T/P. One pt had persistent Gr 2 LVSD 3 mo after the initial event. The pt with Gr 3 LVSD had extensive chest wall disease and died of PD and possibly CHF 2 mo after treatment termination. Conclusions: We observed Gr 1–3 LVSD in patients with HER2+ MBC who received dual MoAB treatment directed at HER2, in which very strict cardiac surveillance guidelines were required. One of 11 pts achieved PR and 1 pt had symptomatic CHF thus far. It is unknown whether the other events would have become symptomatic if treatment had continued. Further evaluation of the efficacy of combination T with P is required to define the overall risk and benefit. No significant financial relationships to disclose.


2017 ◽  
Vol 10 (4) ◽  
pp. 195-197 ◽  
Author(s):  
Nadia Gabarin ◽  
Edgar T Jaeggi ◽  
Danna A Spears ◽  
Mathew Sermer ◽  
Candice K Silversides ◽  
...  

The occurrence of a maternal and fetal tachyarrhythmia together in pregnancy is exceedingly rare. We report a case of a persistent fetal atrial ectopic tachycardia occurring in conjunction with a maternal atrial tachycardia with left ventricular systolic dysfunction. Amiodarone was effective in treating both maternal and fetal arrhythmias.


2021 ◽  
Vol 23 (Supplement_G) ◽  
Author(s):  
Giuliana Cimino ◽  
Giada Colombo ◽  
Maria Giulia Bellicini ◽  
Ludovica Amore ◽  
Angelica Cersosimo ◽  
...  

Abstract Aims Granulomatosis with polyangiitis (GPA) is a systemic necrotizing vasculitis, which could potentially affect any organ system. However, there have only been a few reports on cardiac involvement. In fact, it most commonly involves the sinuses, lungs, and kidneys with necrotizing granulomatous vasculitis. In 12% of a large series of patients with GPA there was cardiac involvement, largely manifested by pericarditis and coronary arteritis. Methods and results We describe a rare case of a 23-year-old girl, with no pathological history, at exception of a recent flu-like syndrome for which she carried out the search for SARS-CoV-2 RNA through nasopharyngeal swab, results negative. After a month, she went to the emergency department for a syncopal episode and subsequent head trauma. On this occasion, echocardiogram performed showed the presence of left ventricular systolic dysfunction due to hypokinesia of the middle distal segments; CT angiography of the chest revealed the presence of pulmonary embolism. For this reason, the patient was admitted to the cardiac intensive care unit, where EKG shown anterolateral myocardial infarction with ST elevation and immediately was performed coronary angiography, that evidenced two-vessel disease, with subsequent ineffective attempt to angioplasty. Due to the intercurrent appearance of hyposthenia and paraesthesia in the left upper limb, CT angiography of the brain was performed with detection of lower right pre central frontal hypodensity, suspected for recent ischaemic lesion and hypodensity of the right carotid artery as recent thrombosis. In light of the multi-organ involvement of ischaemic nature and the young age of the patient, rheumatological evaluation was carried out, with execution of a laboratory tests that showed the presence of positivity for ANCA anti-PR3 antibodies, on the basis of which was diagnosed GPA, and rituximab therapy was immediately initiated, with clinical benefit. Conclusions Cardiac involvement of GPA was first reported by Wegener in 1936. Classical or generalized GPA is characterized by necrotizing granulomatous vasculitis of the upper and lower respiratory tract together with glomerulonephritis. Widespread disseminated vasculitis involving both small arteries and veins occurs to a greater or lesser degree as the disease progresses. A localized form of GPA limited primarily to the upper and lower respiratory tracts has been described. Despite histopathological diagnosis of GPA, with autoantibodies against to circulatory neutrophilic cytoplasmic antigens, we can diagnose GPA easily and early. GPA must be kept in mind as the differential diagnosis of new onset cardiomyopathy, especially in the existence of pulmonary and renal pathologies. The clinical presentation of GPA can be so diverse that the list of differential diagnoses is vast, ranging from infections (fungal, bacterial, and mycobacterial) to other vasculitides, including Henoch–Schönlein purpura, sarcoidosis, Behcet syndrome, and malignancies. Despite that involving the heart is well described, significant cardiac complications occurring during the course of the disease are rare.


Herz ◽  
2015 ◽  
Vol 40 (7) ◽  
pp. 989-996 ◽  
Author(s):  
Giovanni Cioffi ◽  
Ombretta Viapiana ◽  
Federica Ognibeni ◽  
Andrea Dalbeni ◽  
Davide Gatti ◽  
...  

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Adam D DeVore ◽  
Eric Yow ◽  
Mitchell W Krucoff ◽  
Linda K Shaw ◽  
Karen Chiswell ◽  
...  

Background: Clinical trial data suggest a modest improvement in outcomes when coronary bypass surgery (CABG) is added to medical therapy for patients with stable coronary artery disease (CAD) and left ventricular systolic dysfunction (LVSD). However, limited data are available to understand the impact of percutaneous coronary interventions (PCI) on mortality for patients with stable CAD and LVSD. Methods: We studied 901 patients in the Duke Databank for Cardiovascular Diseases. All patients underwent a coronary angiogram at Duke University for suspected CAD between 1995 and 2012. Patients included in the analysis all had CAD amenable to PCI (>50% stenosis) in at least 1 vessel, reduced LVEF (< 35%), and stable CAD. Patients with CCS class III or IV angina or CABG within 30 days were excluded. Of 901 patients, 259 were treated with PCI and 642 were treated with medical therapy. Propensity scores for PCI, created from 24 different variables (including age, LVEF, comorbid conditions, and medications), were used to assemble a matched cohort of 444 patients (222 pairs) receiving PCI or medical therapy alone. A survival curve was derived using the Kaplan-Meier method and the hazard ratio (HR) for mortality was estimated using Cox regression modeling. Results: In the matched cohort, the mean age was 63 years with 321 (72%) males. Three-vessel disease was present in 70 patients (16%). The mean EF was 27% and 153 (35%) reported NYHA Class III/IV symptoms; 392 (88%) were treated with beta-blockers and 378 (85%) with ACE-inhibitors or ARBs. Over 12 years of follow-up, patients in both groups had similar mortality (Figure), HR 0.87 (95% confidence interval 0.68-1.10). Conclusion: In this well-profiled, propensity-matched cohort, there was no significant difference in long-term mortality between patients treated with medical therapy alone or with medical therapy plus PCI. More studies are needed to understand the impact of PCI on other outcomes including symptoms and functional status.


Sign in / Sign up

Export Citation Format

Share Document